bioAffinity Technologies Launches New Lung Cancer Test Case Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy BIAF?
Source: NASDAQ.COM
- Non-invasive Testing Advantage: bioAffinity Technologies' CyPath Lung test successfully provided a 'Unlikely Malignancy' result for a 71-year-old high-risk patient, avoiding costly and risky lung biopsy procedures, thereby reducing healthcare costs.
- Clinical Effectiveness: The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules less than 20 millimeters, indicating its potential in early lung cancer screening and effectively supporting physician decision-making.
- Patient Psychological Support: By alleviating patient anxiety regarding invasive procedures, CyPath Lung not only boosted patient confidence but also provided physicians with a reliable basis for follow-up imaging, promoting better medical decisions.
- Stock Performance Volatility: Despite BIAF's stock closing down 9.91% at $1.91 on Monday, it rebounded in pre-market trading, rising 15.64% to $2.20, reflecting positive market response to the new test case.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIAF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIAF
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioAffinity's CyPath Lung Test Shows Promising Results and Sales Growth
- Successful Non-Invasive Test Case: BioAffinity's CyPath Lung test was successfully applied to a 71-year-old former smoker, revealing multiple lung nodules, with results indicating inflammation rather than cancer, showcasing the test's effectiveness and potential in real-world applications.
- Significant Sales Growth Expected: The company anticipates that sales of the CyPath Lung test will exceed $963,000 in 2026, representing more than a 100% increase from 2025, reflecting strong market demand for non-invasive cancer detection.
- Stock Price Surge: BioAffinity's stock soared approximately 85% on Monday, breaking above its 200-day moving average, with a cumulative increase of over 160% in the past week, indicating strong investor confidence in the company's future prospects.
- Financial Condition Changes: Despite total revenue declining to $6.2 million and net loss widening to $14.9 million in 2025, the company raised $16.9 million to focus on the development of the CyPath Lung test, demonstrating its commitment to strategic transformation.
See More
BIAF Shares Jump 85%, Exceed 200-DMA for the First Time in Almost a Year – Here's What's Fueling the Surge
CyPath Lung Test Overview: BioAffinity Technologies' CyPath Lung test utilizes AI to analyze sputum samples, identifying potential cancer signals without invasive procedures. The test has shown promising results in a case study involving a 71-year-old former smoker.
Sales Projections: The company anticipates that sales of the CyPath Lung test will more than double by 2026, following an 87% increase in revenue for the full year 2025, reaching $963,000.
Stock Performance: BioAffinity's stock surged by 98% after reporting significant revenue growth, breaking above its 200-day moving average for the first time since April 2025, with a year-to-date gain of over 300%.
Research and Development: The company is advancing research in COPD and asthma diagnostics, with patient studies planned for this year, while also raising $16.9 million to fund growth initiatives.
See More
bioAffinity Technologies Launches New Lung Cancer Test Case Study
- Non-invasive Testing Advantage: bioAffinity Technologies' CyPath Lung test successfully provided a 'Unlikely Malignancy' result for a 71-year-old high-risk patient, avoiding costly and risky lung biopsy procedures, thereby reducing healthcare costs.
- Clinical Effectiveness: The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules less than 20 millimeters, indicating its potential in early lung cancer screening and effectively supporting physician decision-making.
- Patient Psychological Support: By alleviating patient anxiety regarding invasive procedures, CyPath Lung not only boosted patient confidence but also provided physicians with a reliable basis for follow-up imaging, promoting better medical decisions.
- Stock Performance Volatility: Despite BIAF's stock closing down 9.91% at $1.91 on Monday, it rebounded in pre-market trading, rising 15.64% to $2.20, reflecting positive market response to the new test case.
See More
BioAffinity Technologies Shares Surge 20% on Positive CyPath Lung Test Results
- Stock Surge: BioAffinity Technologies (BIAF) shares jumped approximately 20% in pre-market trading on Tuesday, reflecting strong market confidence in the company's future following a positive case study update.
- Successful Non-Invasive Test: The CyPath Lung test was administered to a 71-year-old former smoker, yielding a negative result for malignancy, which allowed the patient and physician to opt for a follow-up CT scan in three months, showcasing the test's effectiveness in assessing lung cancer risk.
- CT Scan Confirmation: Subsequent CT scans revealed that the suspicious lung nodules had resolved, confirming they were likely due to inflammation rather than cancer, thereby validating the accuracy and reliability of the CyPath Lung test.
- Significant Trading Volume: Over 4 million shares changed hands in pre-market trading, significantly surpassing the average of 300,000 shares, indicating heightened investor interest and engagement with BioAffinity.
See More
bioAffinity Technologies 2025 Financial Overview
- Financial Performance: bioAffinity Technologies reported a FY GAAP EPS of -$8.66 with revenues of $6.2 million, indicating challenges in revenue growth and reflecting pressure in market competition.
- Operating Expense Reduction: Operating expenses decreased by 9% to $16.7 million in 2025, primarily due to strategic actions aimed at streamlining and reducing lab operation costs, which alleviated some financial pressure.
- R&D Investment: Research and development expenses were $1.4 million in 2025, slightly lower than the prior year, demonstrating the company's commitment to ongoing investment in lab operations and preclinical development despite financial losses.
- Cash Flow Status: As of December 31, 2025, cash and cash equivalents were $6.5 million, a significant increase from $1.1 million at the end of 2024, primarily due to $16.9 million raised in multiple financings in 2025 to support ongoing operations.
See More
bioAffinity Technologies Stock Soars on Strong CyPath Lung Results
- CyPath Lung Revenue Surge: bioAffinity reported an 87% year-over-year increase in CyPath Lung revenue for 2025, with test volumes soaring by 99%, indicating a 67% rise in orders from physician offices and clinics, reflecting enhanced market awareness and positive clinical experiences.
- Widening Net Loss: Despite revenue growth, bioAffinity's net loss widened from $9 million to $14.9 million, primarily due to changes in the fair value of warrants, expanded sales activities, and increased clinical development spending, highlighting financial pressures during the company's strategic shift.
- Improved Cash Flow: The company's cash and cash equivalents improved to $6.5 million at year-end, up from $1.1 million last year, bolstered by approximately $16.9 million raised in 2025 financings, enhancing its financial foundation for future business expansion.
- Optimistic Future Outlook: bioAffinity expects CyPath Lung unit sales to increase by over 100% in 2026, indicating that its efforts in commercialization and clinical validation are likely to drive future revenue growth and further solidify its market position.
See More
BioAffinity's CyPath Lung Test Shows Promising Results and Sales Growth
- Successful Non-Invasive Test Case: BioAffinity's CyPath Lung test was successfully applied to a 71-year-old former smoker, revealing multiple lung nodules, with results indicating inflammation rather than cancer, showcasing the test's effectiveness and potential in real-world applications.
- Significant Sales Growth Expected: The company anticipates that sales of the CyPath Lung test will exceed $963,000 in 2026, representing more than a 100% increase from 2025, reflecting strong market demand for non-invasive cancer detection.
- Stock Price Surge: BioAffinity's stock soared approximately 85% on Monday, breaking above its 200-day moving average, with a cumulative increase of over 160% in the past week, indicating strong investor confidence in the company's future prospects.
- Financial Condition Changes: Despite total revenue declining to $6.2 million and net loss widening to $14.9 million in 2025, the company raised $16.9 million to focus on the development of the CyPath Lung test, demonstrating its commitment to strategic transformation.
See More
BIAF Shares Jump 85%, Exceed 200-DMA for the First Time in Almost a Year – Here's What's Fueling the Surge
CyPath Lung Test Overview: BioAffinity Technologies' CyPath Lung test utilizes AI to analyze sputum samples, identifying potential cancer signals without invasive procedures. The test has shown promising results in a case study involving a 71-year-old former smoker.
Sales Projections: The company anticipates that sales of the CyPath Lung test will more than double by 2026, following an 87% increase in revenue for the full year 2025, reaching $963,000.
Stock Performance: BioAffinity's stock surged by 98% after reporting significant revenue growth, breaking above its 200-day moving average for the first time since April 2025, with a year-to-date gain of over 300%.
Research and Development: The company is advancing research in COPD and asthma diagnostics, with patient studies planned for this year, while also raising $16.9 million to fund growth initiatives.
See More
bioAffinity Technologies Launches New Lung Cancer Test Case Study
- Non-invasive Testing Advantage: bioAffinity Technologies' CyPath Lung test successfully provided a 'Unlikely Malignancy' result for a 71-year-old high-risk patient, avoiding costly and risky lung biopsy procedures, thereby reducing healthcare costs.
- Clinical Effectiveness: The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules less than 20 millimeters, indicating its potential in early lung cancer screening and effectively supporting physician decision-making.
- Patient Psychological Support: By alleviating patient anxiety regarding invasive procedures, CyPath Lung not only boosted patient confidence but also provided physicians with a reliable basis for follow-up imaging, promoting better medical decisions.
- Stock Performance Volatility: Despite BIAF's stock closing down 9.91% at $1.91 on Monday, it rebounded in pre-market trading, rising 15.64% to $2.20, reflecting positive market response to the new test case.
See More
BioAffinity Technologies Shares Surge 20% on Positive CyPath Lung Test Results
- Stock Surge: BioAffinity Technologies (BIAF) shares jumped approximately 20% in pre-market trading on Tuesday, reflecting strong market confidence in the company's future following a positive case study update.
- Successful Non-Invasive Test: The CyPath Lung test was administered to a 71-year-old former smoker, yielding a negative result for malignancy, which allowed the patient and physician to opt for a follow-up CT scan in three months, showcasing the test's effectiveness in assessing lung cancer risk.
- CT Scan Confirmation: Subsequent CT scans revealed that the suspicious lung nodules had resolved, confirming they were likely due to inflammation rather than cancer, thereby validating the accuracy and reliability of the CyPath Lung test.
- Significant Trading Volume: Over 4 million shares changed hands in pre-market trading, significantly surpassing the average of 300,000 shares, indicating heightened investor interest and engagement with BioAffinity.
See More
bioAffinity Technologies 2025 Financial Overview
- Financial Performance: bioAffinity Technologies reported a FY GAAP EPS of -$8.66 with revenues of $6.2 million, indicating challenges in revenue growth and reflecting pressure in market competition.
- Operating Expense Reduction: Operating expenses decreased by 9% to $16.7 million in 2025, primarily due to strategic actions aimed at streamlining and reducing lab operation costs, which alleviated some financial pressure.
- R&D Investment: Research and development expenses were $1.4 million in 2025, slightly lower than the prior year, demonstrating the company's commitment to ongoing investment in lab operations and preclinical development despite financial losses.
- Cash Flow Status: As of December 31, 2025, cash and cash equivalents were $6.5 million, a significant increase from $1.1 million at the end of 2024, primarily due to $16.9 million raised in multiple financings in 2025 to support ongoing operations.
See More
bioAffinity Technologies Stock Soars on Strong CyPath Lung Results
- CyPath Lung Revenue Surge: bioAffinity reported an 87% year-over-year increase in CyPath Lung revenue for 2025, with test volumes soaring by 99%, indicating a 67% rise in orders from physician offices and clinics, reflecting enhanced market awareness and positive clinical experiences.
- Widening Net Loss: Despite revenue growth, bioAffinity's net loss widened from $9 million to $14.9 million, primarily due to changes in the fair value of warrants, expanded sales activities, and increased clinical development spending, highlighting financial pressures during the company's strategic shift.
- Improved Cash Flow: The company's cash and cash equivalents improved to $6.5 million at year-end, up from $1.1 million last year, bolstered by approximately $16.9 million raised in 2025 financings, enhancing its financial foundation for future business expansion.
- Optimistic Future Outlook: bioAffinity expects CyPath Lung unit sales to increase by over 100% in 2026, indicating that its efforts in commercialization and clinical validation are likely to drive future revenue growth and further solidify its market position.
See More
